G protein-coupled estrogen receptor 1 (GPER1) (GPER1)

G protein-coupled estrogen receptor 1 (GPER1), also known as GPR30, is a seven-transmembrane receptor that mediates rapid, non-genomic signaling in response to 17β-estradiol and other estrogenic compounds [2, 4]. Unlike classical nuclear estrogen receptors (ERα and ERβ), GPER1 is primarily localized to the plasma membrane and endoplasmic reticulum, where its activation triggers intracellular cascades such as the cAMP/PKA, PI3K/Akt, and MAPK/ERK pathways [4, 25]. In bone biology, GPER1 is recognized as a key estrogen receptor-independent target because it promotes osteoblast proliferation, differentiation, and mineralization through mechanisms distinct from traditional genomic transcription [1, 3, 5]. Studies have shown that GPER1 activation upregulates essential osteogenic factors like Runx2 and alkaline phosphatase, making it a potential therapeutic target for treating osteoporosis and other bone-loss disorders [2, 3]. Furthermore, GPER1 expression is often altered in bone-related malignancies such as osteosarcoma, where it may influence tumor progression and metastasis [9, 19]. Pharmacological agents targeting GPER1, including the selective agonist G-1 and antagonists like G-15, are being investigated for their ability to modulate bone metabolism while potentially minimizing the side effects associated with classical estrogen therapy [5, 9].

Other names

GPR30G-protein coupled estrogen receptor 1Membrane estrogen receptormEREstrogen receptor-independent osteoblastic targets

Activation of GPER1 triggers rapid non-genomic signaling pathways, including the stimulation of adenylyl cyclase to increase cAMP levels, mobilization of intracellular calcium, and activation of the PI3K/Akt and MAPK/ERK kinase cascades [4, 25]. In osteoblasts, these signaling events promote cell survival and differentiation by upregulating the expression of osteogenic markers such as Runx2, alkaline phosphatase, and osteocalcin, ultimately enhancing bone formation and mineralization [2, 3].